Cynata Therapeutics Valuation
| CYYNF Stock | USD 0.11 0.00 0.00% |
Cynata Therapeutics seems to be overvalued based on Macroaxis valuation methodology. Our model approximates the value of Cynata Therapeutics from analyzing the firm fundamentals such as Current Valuation of 12.47 M, profit margin of (0.70) %, and Return On Equity of -0.21 as well as examining its technical indicators and probability of bankruptcy. In general, most investors favor locking in undervalued instruments and disposing overvalued instruments since, at some point, asset prices and their ongoing real values will blend.
Overvalued
Today
Please note that Cynata Therapeutics' price fluctuation is out of control at this time. Calculation of the real value of Cynata Therapeutics is based on 3 months time horizon. Increasing Cynata Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Our valuation method for Cynata Therapeutics Limited is useful when determining the fair value of the Cynata pink sheet, which is usually determined by what a typical buyer is willing to pay for full or partial control of Cynata Therapeutics. Since Cynata Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Cynata Pink Sheet. However, Cynata Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.11 | Real 0.0844 | Hype 0.11 | Naive 0.11 |
The real value of Cynata Pink Sheet, also known as its intrinsic value, is the underlying worth of Cynata Therapeutics Company, which is reflected in its stock price. It is based on Cynata Therapeutics' financial performance, assets, liabilities, growth prospects, management team, or industry conditions. The intrinsic value of Cynata Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Cynata Therapeutics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Cynata Therapeutics Limited helps investors to forecast how Cynata pink sheet's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Cynata Therapeutics more accurately as focusing exclusively on Cynata Therapeutics' fundamentals will not take into account other important factors: Cynata Therapeutics Valuation Ratios as Compared to Competition
Comparative valuation techniques use various fundamental indicators to help in determining Cynata Therapeutics's current stock value. Our valuation model uses many indicators to compare Cynata Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Cynata Therapeutics competition to find correlations between indicators driving Cynata Therapeutics's intrinsic value. More Info.Cynata Therapeutics Limited is number one stock in price to book category among related companies. It is number one stock in price to sales category among related companies fabricating about 2.08 of Price To Sales per Price To Book. Comparative valuation analysis is a catch-all model that can be used if you cannot value Cynata Therapeutics by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Cynata Therapeutics' Pink Sheet. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Cynata Therapeutics' earnings, one of the primary drivers of an investment's value.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Cynata Therapeutics' worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Cynata Therapeutics and how it compares across the competition.
About Cynata Therapeutics Valuation
The pink sheet valuation mechanism determines the current worth of Cynata Therapeutics Limited on a weekly basis. We use both absolute as well as relative valuation methodologies to arrive at the intrinsic value of Cynata Therapeutics Limited. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Cynata Therapeutics based exclusively on its fundamental and basic technical indicators. By analyzing Cynata Therapeutics's financials, quarterly and monthly indicators, and its related drivers such as dividends, operating cash flow, and various types of growth rates, we attempt to find the most accurate representation of Cynata Therapeutics's intrinsic value. In some cases, mostly for established, large-cap companies, we also incorporate more traditional valuation methods such as dividend discount, discounted cash flow, or asset-based models. As compared to an absolute model, our relative valuation model uses a comparative analysis of Cynata Therapeutics. We calculate exposure to Cynata Therapeutics's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Cynata Therapeutics's related companies.Cynata Therapeutics Limited, together with its subsidiaries, develops and commercializes a proprietary mesenchymal stem cell technology under the Cymerus brand for human therapeutic use in Australia. Cynata Therapeutics Limited was founded in 2011 and is based in Cremorne, Australia. Cynata Therapeutics operates under Biotechnology classification in the United States and is traded on OTC Exchange.
8 Steps to conduct Cynata Therapeutics' Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Cynata Therapeutics' potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Cynata Therapeutics' valuation analysis, follow these 8 steps:- Gather financial information: Obtain Cynata Therapeutics' financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Cynata Therapeutics' revenue streams: Identify Cynata Therapeutics' primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Cynata Therapeutics' industry and market trends, including the size of the market, growth rate, and competition.
- Establish Cynata Therapeutics' growth potential: Evaluate Cynata Therapeutics' management, business model, and growth potential.
- Determine Cynata Therapeutics' financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Cynata Therapeutics' estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Cynata Therapeutics Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines. Note, investing in growth stocks can be very risky. If the company such as Cynata Therapeutics does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 143.3 M | |
| Retained Earnings | -58.3 M |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cynata Therapeutics Limited. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. You can also try the Stocks Directory module to find actively traded stocks across global markets.
Complementary Tools for Cynata Pink Sheet analysis
When running Cynata Therapeutics' price analysis, check to measure Cynata Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cynata Therapeutics is operating at the current time. Most of Cynata Therapeutics' value examination focuses on studying past and present price action to predict the probability of Cynata Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cynata Therapeutics' price. Additionally, you may evaluate how the addition of Cynata Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine |